Abstract:Abstract Context Glioblastoma multiforme (GBM) is a malignant and aggressive primary brain tumor with a poor prognosis. This adverse prognosis is due to the tumor's tendency for advancement and recurrence caused by highly intrusive nature of the persisting GBM cells that actively escape from the main tumor mass into the surrounding normal brain tissue. On the basis of biomarker illustration, it can be classified into molecular subgroups. Aims (1) To determine the expression of IDH1, ATRX, p53, and Ki67 by immunohistochemistry, in a cohort of GBMs. (2) To determine whether altered protein expression of any of these growth-control genes in GBM will show association with patient survival. (3) To establish prognostically distinct molecular subgroups of GBM, irrespective of histopathological diagnosis. Results In this prospective observational study, 35 histologically diagnosed cases of glioblastoma were enrolled. The mean age at the time of presentation was 43.46 ± 17.25 years with a male:female ratio of 1.3:1. Of the 35 cases, microvascular proliferation was seen in 23 cases. Large foci of necrosis (>50%) were seen in 10 cases and 27 cases had mitotic count ≥ 5/high power field (HPF). Of 35 cases, 5 (14.3%) cases showed IDH1 immunopositivity and 30 (85.7%) cases were negative for IDH1. ATRX was retained in 24 (68.6%) cases, while it was lost in 11 (31.4%) cases. The p53 immunoexpression was seen in 31 (88.6%) cases, whereas p53 was negative in 4 (11.4%) cases. The overall median survival (OS) was 6 months. In two protein pairs, the three compositions were IDH1–/p53+ (74.3%), ATRX +/IDH1– (62.9%), and ATRX +/p53+ (57.1%). Combined three-protein immunohistochemical analysis revealed five different molecular variants. Also, 8.6% (3/35) of the samples had aberrant protein expression of all three proteins, i.e., ATRX–/p53 +/IDH1 + , while 11.4% (4/35) were wild-type protein expression group, i.e., ATRX +/p53–/IDH1–. Conclusion In patients with single protein expression, Kaplan–Meier survival analysis showed statistically better OS in IDH1 mutant glioblastomas. In cases with double protein pairs, IDH1/p53 revealed statistically significant association with better median OS. The survival analysis of patients with IDH1/ATRX/p53 protein combinations also denoted a better OS. Hence, GBM can be grouped into prognostically relevant subgroups using these protein expression signatures individually, as well as the combined protein expression signatures.

Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1 R132H mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss.

Polymeric Immunoglobulin Receptor Expression Is Predictive Of Poor Prognosis In Glioma Patients

Polymeric Immunoglobulin Receptor Expression is Predictive of Poor Prognosis in Glioma Patients.

IDH1, ATRX, p53, and Ki67 Expression in Glioblastoma patients: Their Clinical and Prognostic Significance—A Prospective Study

Predicting IDH mutation status as well as Ki-67 and p53 expression in high-grade gliomas using amide proton transfer-weighted and arterial spin labeling MRI

ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients.

Identification of New Biomarkers Associated With IDH Mutation and Prognosis in Astrocytic Tumors Using NanoString nCounter Analysis System.

Downregulated expression of HSP27 in human low-grade glioma tissues discovered by a quantitative proteomic analysis

Diffuse Isocitrate Dehydrogenase–Mutant Gliomas With Histone H3 Alterations Are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis

Immunostaining of IDH-1 R 132 H and ATRX proteins in the classification of adult glioblastomas

Genomic profiling and prognostic factors of H3 K27M‐mutant spinal cord diffuse glioma

Identification of robust diagnostic and prognostic gene signatures in different grades of gliomas: a retrospective study

Prognostic biomarker HIF1α and its correlation with immune infiltration in gliomas

Prognosis and therapeutic significance of IGF-1R-related signaling pathway gene signature in glioma

Gene Expression Profiling of Glioblastoma to Recognize Potential Biomarker Candidates

Genomic profiling identified novel prognostic biomarker in Chinsese glioma patients.

The Roles of AGTRAP, ALKBH3, DIVERSIN, NEDD8 and RRM1 in Glioblastoma Pathophysiology and Prognosis

BI-06 * ATRX LOSS IN CHINESE ADULT DIFFUSE ASTROCYTOMAS CORRELATES WITH IDH1 AND TP53 MUTATION AND PREDICTS BETTER OUTCOME IN TP53 MUTATED PATIENTS

Analysis of CD137L and IL-17 Expression in Tumor Tissue As Prognostic Indicators for Gliblastoma.

A multivariate retrospective analysis of high-grade gliomas: Survival and prognostic factors

Biom-11. Prognostic Value Of H3K27Me3 And Ezh2 In Astrocytoma, Idh-Mutant